Immune Checkpoint Inhibitors Combined with Chemotherapy in The Treatment of Lung Cancer

Abstract

Immune checkpoint inhibitor (ICI) therapy is the most commonly used immunotherapy regimen. The clinical application of this medicine has been authorized for the treatment of several neoplasms such as melanoma, renal, head and neck, bladder, etc. Lung cancer treatment has witnessed significant advancements, positioning it as a pivotal component within the broader framework of comprehensive lung cancer management. However, due to the heterogeneity of tumors and the intricacy of the microenvironment of tumors, the effective rate of ICIs alone is low in non-selected patients. Surgery, chemotherapy, radiotherapy, targeted therapy, and other treatments can have synergistic effects with immunotherapy, and combination therapy has become a hotspot for exploration. This article centers on the research advancements in the therapeutic approach of combining immune checkpoint inhibitors (ICIs) with chemotherapy. This text offers an introductory overview of the distinct mechanisms of action associated with these two treatment modalities, highlighting the significance of their combined use in the context of lung cancer treatment. The objective is to offer a reference point for future clinical treatments of lung cancer.